LEO 32731 - A Phase I Study in Healthy Subjects

Summary

LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis. The aim (s) of this Study are to determine: * The safety and tolerability of the Study Drug and any side effects that might be associated with it * The Study will also measure how much of the Study Drug that gets into the blood and how long time it takes for the body to remove it.

Timeline

Start

2015-07

Primary completion

2015-12

Completion

2015-12

Drugs

Indications